VERU research facilities include state-of-the-art laboratories and clinical areas.
Key facilities include:
• The Low-vision Suite featuring a new Vicon mobility analysis system,
• The Diagnostic Suite which includes anterior (Zeiss) and posterior (Spectralis) OCT's, Microperimeter (MP1), fundus camera, Keeler-Konan Pocklington wide-field specular photomicroscope,
• An Anterior Eye Research Suite, incorporating a room-sized environmental chamber which allows independent manipulation of temperature, wind speed and humidity,
• The Contact Lens Research Suite, which features a Shack-Hartmann wavefront sensor, IOL Master and a power refractor,
• The Psychophysics Suite with Cambridge Research Systems Visage and SR Research EyeLink 1000 eye tracker.
In addition, four dedicated clinical testing rooms enable clinical projects including the glaucoma referral refinement project in collaboration with Addenbrooke's Hospital.
Full access to Tissue Laboratories in the department of Life Sciences include a specular microscope for observation and analysis of the corneal endothelium, flow cytometer for cell surface protein expression studies and polymerase chain reaction for DNA amplification.
Our researchers investigate mobility and co-ordination in low vision patients using the most advanced gait lab in the UK, modelled on one in the Hospital for Special Surgery, New York.
VERU has the advantage of full access to all Postgraduate Medical Institute's (PMI) facilities. The PMI was developed via a significant investment of £12m in 2008 (as proposed in our RAE 2008 strategic plans) and has attracted an extensive network of inter-disciplinary collaborators. It has partnered with 21 external member organisations, including all NHS acute hospitals, primary care and mental health trusts and specialist tertiary care (St. Andrews Centre for Burns and Plastic Surgery and the Essex Cardiothoracic Centre) in Essex, along with Essex County Council, Ramsay and Nuffield Hospitals, numerous hospices and the Royal Society for Public Health. With a footprint encompassing five counties, VERU has unfettered access to a population of 10 million potential patient beneficiaries.
We have full access to the fast-developing ARU MedTech campus, launched by Lord Howe in 2012. This private sector-led initiative offers 1.7m square feet of innovation space in partnership with three local councils.
An additional investment of £300k in 2012 enabled the PMI to set up Anglia Ruskin Clinical Trials Unit (ARCTU).
For further information please contact Roger Buckley.
Ousler GW et al. Methodologies for the study of ocular surface disease. Ocul Surf 2005; 3: 143-54
González-García M et al: Invest Ophthalmol Vis Sci 2007; 48: 4026-32
Ousler GW et al: Current Medical Research and Opinion 2008; 24/2: 335-41